Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference By: ACCESSWIRE August 08, 2023 at 08:30 AM EDT CEO Josh Riggs will be meeting with registered investors on Tuesday, August 15, 2023 IRVINE, CA / ACCESSWIRE / August 8, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference taking place on August 14-15th, 2023. Josh Riggs, CEO of Oncocyte, will be meeting 1x1 or in small groups with registered investors on Tuesday, August 15, 2023. Interested investors can register for the conference with their Needham representative. About OncocyteOncocyte is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information, visit https://oncocyte.com/ VitaGraft™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation. CONTACT:Stephanie PrincePCG Advisory(646) 863-6341sprince@pcgadvisory.com SOURCE: Oncocytevia PRISM Mediawire, LLC View source version on accesswire.com: https://www.accesswire.com/772720/Oncocyte-to-Participate-in-8th-Annual-Needham-Virtual-MedTech-Diagnostics-11-Conference Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference By: ACCESSWIRE August 08, 2023 at 08:30 AM EDT CEO Josh Riggs will be meeting with registered investors on Tuesday, August 15, 2023 IRVINE, CA / ACCESSWIRE / August 8, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference taking place on August 14-15th, 2023. Josh Riggs, CEO of Oncocyte, will be meeting 1x1 or in small groups with registered investors on Tuesday, August 15, 2023. Interested investors can register for the conference with their Needham representative. About OncocyteOncocyte is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information, visit https://oncocyte.com/ VitaGraft™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation. CONTACT:Stephanie PrincePCG Advisory(646) 863-6341sprince@pcgadvisory.com SOURCE: Oncocytevia PRISM Mediawire, LLC View source version on accesswire.com: https://www.accesswire.com/772720/Oncocyte-to-Participate-in-8th-Annual-Needham-Virtual-MedTech-Diagnostics-11-Conference
CEO Josh Riggs will be meeting with registered investors on Tuesday, August 15, 2023 IRVINE, CA / ACCESSWIRE / August 8, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference taking place on August 14-15th, 2023. Josh Riggs, CEO of Oncocyte, will be meeting 1x1 or in small groups with registered investors on Tuesday, August 15, 2023. Interested investors can register for the conference with their Needham representative. About OncocyteOncocyte is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test, DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information, visit https://oncocyte.com/ VitaGraft™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation. CONTACT:Stephanie PrincePCG Advisory(646) 863-6341sprince@pcgadvisory.com SOURCE: Oncocytevia PRISM Mediawire, LLC View source version on accesswire.com: https://www.accesswire.com/772720/Oncocyte-to-Participate-in-8th-Annual-Needham-Virtual-MedTech-Diagnostics-11-Conference